<DOC>
	<DOCNO>NCT00859079</DOCNO>
	<brief_summary>The aim investigator study compare first time efficacy safety intravenously administer GLP-1 establish intravenous insulin regimen hyperglycaemic type 2 diabetic patient .</brief_summary>
	<brief_title>Efficacy GLP-1 Infusion Comparison Insulin Infusion Protocol Reach Normoglycemia Type 2 Diabetic Patients</brief_title>
	<detailed_description>Intervention study patient acute myocardial infraction cardiac surgery , use intravenously administer human insulin , suggest normalization hyperglycemia reduce morbidity well mortality patient . Insulin-based regimen require frequent blood glucose measurement adjustment infusion rate achieve normoglycemia . In addition , hypoglycaemia frequent important side effect . Glucagon-Like-Peptide 1 ( GLP-1 ) insulinotropic , glucagonostatic gastrointestinal hormone lower glucose glycemia-dependent manner therefore cause hypoglycemia . The aim study compare first time efficacy safety intravenously administer GLP-1 establish intravenous insulin regimen hyperglycaemic type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Type 2 diabetes mellitus Fasting glycemia 150 mg/dl Signed informed consent Patients heart failure &gt; NYHA II Uncontrolled hypertension Impaired kidney function ( creatinine &gt; 3 mg/dl ) Acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>diabetes mellitus type 2 , GLP-1 , insulin infusion</keyword>
</DOC>